Back to News & Stories
PxWire Volume 16, Issue No. 2
Check out the latest issue of PxWire here! And see key highlights below:
- In FY25, new PrEP initiations fell 41% compared to FY24—with overall decreases of 54% among men and 53% among non-pregnant, non-breastfeeding women.
- On April 14, the US State Department and Global Fund expanded their LEN for PrEP commitment from 2 to 3 million people over three years. While welcome, this falls short of what’s needed for meaningful scale-up, with no guarantees the product will reach those who need it most.
- A growing LA-ART pipeline could introduce regimens dosed weekly, monthly, or eventually yearly—reducing drug burden, costs, and strain on health systems. New drug classes may also close treatment gaps for children, adolescents, and people with high viremia, comorbidities, or resistance.